Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Johanna Bigio

Gastroenterology Doral, FL Medical Doctor

NPI 1528179546 CMS profile 68780

8600 Nw 41St St, Doral, FL 33166

Open in the dashboard

General payments

$456

12 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Johanna Bigio of Doral, FL is reported in the CMS Open Payments database as having received $456 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 24th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $117 1
2021 General $147 8
2020 General $192 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Johanna Bigio
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Johanna Bigio were reported at $117. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Johanna Bigio Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $192 $224 $74–$624 $114
2021 $147 $352 $106–$1,054 $132
2022 $0 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $117 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Gilead Sciences, Inc. $204 6 payments
  2. Madrigal Pharmaceuticals $117 1 payment
  3. Janssen Biotech, Inc. $57 1 payment
  4. PBG Puerto Rico LLC $57 3 payments
  5. AbbVie, Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $399 11 payments
  2. Education $57 1 payment
Products named General payments · program years 2020–2025
  1. Epclusa $125 1 payment
  2. REZDIFFRA $117 1 payment
  3. STELARA $57 1 payment
  4. XELJANZ $57 3 payments
  5. INFLECTRA $40 2 payments
  6. MAVYRET $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,932

Median for Internal Medicine: 777

Drug cost

$33,514

Median for Internal Medicine: $73,373

Branded share of claims

15.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 120 $7,574
Linzess Linaclotide Brand 14 $6,954
Dexlansoprazole Dr Dexlansoprazole Brand 32 $4,327
Mesalamine Generic 24 $2,848
Lubiprostone Generic 50 $2,843
Lactulose Generic 115 $1,757
Cholestyramine Light Cholestyramine Brand 57 $1,712
Prevalite Cholestyramine Brand 35 $985
Esomeprazole Magnesium Generic 57 $713
Omeprazole Generic 394 $603

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record